Last reviewed · How we verify
NCT04484116
IOPTH Usefulness for Predicting Successful Surgery in Secondary Hyperparathyroidism
trial testing Intraoperative Paratohormone in Secondary Hyperparathyroidism in 30 participants. Completed in 30 November 2019.
30 November 2019
Quick facts
| Lead sponsor | Hospital General Ajusco Medio |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 July 2017 |
| Primary completion | 30 November 2019 |
| Estimated completion | 30 November 2019 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- Intraoperative Paratohormone
Conditions studied
- Secondary Hyperparathyroidism — all drugs for Secondary Hyperparathyroidism →
Sponsor
Hospital General Ajusco Medio
Who can join
Adults 18 to 90, any sex, with Secondary Hyperparathyroidism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Secondary hyperparathyroidism (SHPT) is a multisystemic syndrome that affects calcium and bone homeostasis in patients with chronic kidney disease (CKD). Despite medical treatment, 1-2% of patients require parathyroidectomy anually. The use of an intraoperative paratohormone protocol (IOPTH) to predict cure still in debate, due to the lack of standardized protocols, the use of different assays and uneven PTH clearance. The aim of this study was to determine the diagnostic accuracy of an IOPTH in patients with SHPT for predicting successful surgery after parathyroidectomy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04484116
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Secondary Hyperparathyroidism
Currently open trials in the same condition.
- NCT06130683 — Single-Cell Sequence Technology Used to Reveal Heterogeneity of Secondary Hyperparathyroidism · active not recruiting
- NCT05880914 — Precision Medicine Approaches to Renal Osteodystrophy · recruiting
- NCT03969329 — A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis · Phase 3 · recruiting
- NCT03633708 — A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemo · Phase 3 · recruiting
Other Hospital General Ajusco Medio trials
Trials by the same sponsor.
- NCT04859881 — Risk Factors for Barotrauma in COVID-19 · completed
- NCT05067881 — Post-COVID-19 Pneumo-hematocele · completed
- NCT03345368 — Effect of rTMS in Combination With a Low-carbohydrate Diet in Patients With Obesity · NA · completed
- NCT05696405 — VATS for Resection of Mediastinal Parathyroids · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04484116 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital General Ajusco Medio
- Last refreshed: 23 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04484116.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing